GSK

CompanyUnited KingdomFounded 2000

RORWikidata

GSK develops 74 assets, the furthest approved, not sold in the US (Aggrenox). Mostly small molecule and antibody acting on pol, ADRB2 and SLC6A2; based in the United Kingdom, founded in 2000.

74
Assets
Furthest stage
Approved, not sold in the US
1
Grant
1,265
Trials
180
Signals

Pipeline

74
  • Aggrenox

    Fixed combination of aspirin and dipyridamole acting as antiplatelet agents

    Approved, not sold in the US, Small molecule, SLC29A1, PDE4B, stroke (Phase 3), coronary artery disease (Phase 3), Partner

  • Albiglutide

    Activates GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon secretion.

    Approved, discontinued in the US and EU, Protein or enzyme, GLP1R, type 2 diabetes, diabetes mellitus (Phase 3)

  • belantamab mafodotin

    Antibody-drug conjugate targeting BCMA

    Approved, Antibody, TNFRSF17, relapsed or refractory multiple myeloma, newly diagnosed multiple myeloma (Phase 3)

71 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

14

In the full profile

  • Evidence behind the mechanisms12
  • Trials1,828
  • Deals3
  • People1
  • Signals20
  • Similar companies6

Papers

Intelligence